Demographic, clinical, and disease characteristics of patients with atrial fibrillation on edoxaban therapy according to the bleeding risk: A report from evaluation of treatment safety in patients with atrial fibrillation on edoxaban therapy in real

被引：0
|
作者：
Avci, Eyup [1 ]
Akgun, Didar Elif [2 ]
Arslan, Ugur [3 ]
Inci, Sinan [4 ]
Yildirim, Ozge Turgay [5 ]
Yenercag, Mustafa [6 ]
Kasap, Mithat [7 ]
Turk, Ugur Onsel [8 ]
机构：
[1] Balikesir Univ, Dept Cardiol, Fac Med, Balikesir, Turkey
[2] Kirklareli Training & Res Hosp, Dept Cardiol, Kirklareli, Turkey
[3] Samsun Training & Res Hosp, Dept Cardiol, Samsun, Turkey
[4] Aksaray Univ Training & Res Hosp, Dept Cardiol, Aksaray, Turkey
[5] Eskisehir City Hosp, Eskisehir, Turkey
[6] Ordu Univ, Dept Cardiol, Fac Med, Ordu, Turkey
[7] Daiichi Sankyo Turkey, Istanbul, Turkey
[8] Izmir Econ Univ, Dept Cardiol, Fac Med, Izmir, Turkey
来源：
ANATOLIAN JOURNAL OF CARDIOLOGY | 2022年 / 26卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
OP-084
引用
收藏
页码：S101 / S103
页数：3
相关论文
共 50 条
  • [11] Demographic, clinical, and disease characteristics of patients with atrial fibrillation on edoxaban therapy: What are the impacts of heart failure? A subgroup analysis from ETAF-TR Study
    Bakhshaliyev, Nijad
    Coner, Ali
    Altin, Cihan
    Balli, Mehmet
    Tasbulak, Omer
    Totan, Sahin
    Turk, Ugur Onsel
    ANATOLIAN JOURNAL OF CARDIOLOGY, 2022, 26 : S43 - S44
  • [12] Edoxaban Versus Warfarin in Patients With Atrial Fibrillation and History of Liver Disease
    Qamar, Arman
    Antman, Elliott M.
    Ruff, Christian T.
    Nordio, Francesco
    Murphy, Sabina A.
    Grip, Laura T.
    Greenberger, Norton J.
    Yin, Ophelia Q. P.
    Choi, Youngsook
    Lanz, Hans J.
    Mercuri, Michele F.
    Braunwald, Eugene
    Giugliano, Robert P.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2019, 74 (02) : 179 - 189
  • [13] Edoxaban Monotherapy in Nonvalvular Atrial Fibrillation Patients with Coronary Artery Disease
    Fukamachi, Daisuke
    Okumura, Yasuo
    Matsumoto, Naoya
    Tachibana, Eizo
    Oiwa, Koji
    Ichikawa, Makoto
    Haruta, Hironori
    Nomoto, Kazumiki
    Arima, Ken
    Hirayama, Atsushi
    JOURNAL OF INTERVENTIONAL CARDIOLOGY, 2022, 2022
  • [14] Effectiveness and safety of edoxaban in patients with atrial fibrillation:data from the Danish Nationwide Cohort
    Nielsen, Peter Bronnum
    Larsen, Torben Bjerregaard
    Skjoth, Flemming
    Sogaard, Mette
    Lip, Gregory Y. H.
    EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPY, 2021, 7 (01) : 31 - 39
  • [15] Relation of Stroke and Bleeding Risk Profiles to Efficacy and Safety of Edoxaban for Cardioversion of Atrial Fibrillation (from the EdoxabaN versus warfarin in subjectS UndeRgoing cardiovErsion of Atrial Fibrillation [ENSURE-AF] Study)
    Lip, Gregory Y. H.
    Merino, Jose L.
    Dan, G. Andrei
    Themistoclakis, Sakis
    Ellenbogen, Kenneth A.
    De Caterina, Raffaele
    Goudev, Assen
    Jin, James
    Melino, Michael
    Winters, Shannon M.
    Goette, Andreas
    AMERICAN JOURNAL OF CARDIOLOGY, 2018, 121 (02): : 193 - 198
  • [16] Efficacy and safety of edoxaban in patients with atrial fibrillation (AF) and severe chronic kidney disease (CKD)
    Lamaida, Norman
    Torella, Giorgio
    Cerciello, Antonio
    EUROPEAN HEART JOURNAL SUPPLEMENTS, 2020, 22 (0N) : N25 - N26
  • [17] Optimal Dose of Edoxaban for Very Elderly Atrial Fibrillation Patients at High Risk of Bleeding: The LEDIOS Registry
    Kim, Ju Youn
    Kim, Juwon
    Park, Seung-Jung
    Park, Kyoung-Min
    Han, Sang-Jin
    Kim, Dae Kyeong
    Park, Yae Min
    Lee, Sung Ho
    Park, Jong Sung
    On, Young Keun
    KOREAN CIRCULATION JOURNAL, 2024, 54 (07) : 398 - 406
  • [18] Effectiveness and safety of edoxaban therapy in daily-care patients with atrial fibrillation. Results from the DRESDEN NOAC REGISTRY
    Koehler, Christina
    Tittl, Luise
    Marten, Sandra
    Naue, Christiane
    Spindler, Marianne
    Stannek, Laura
    Fache, Kristina
    Beyer-Westendorf, Jan
    THROMBOSIS RESEARCH, 2022, 215 : 37 - 40
  • [19] Effectiveness and safety of edoxaban in atrial fibrillation patients from the ETNA-AF global registry
    De Caterina, R.
    Wang, R.
    Shi, L.
    Pecen, L.
    Ye, X.
    Reimitz, P. -E.
    Chen, C.
    Unverdorben, M.
    Giugliano, R. P.
    EUROPEAN HEART JOURNAL, 2021, 42 : 556 - 556
  • [20] Characteristics of patients initiated on edoxaban in Europe: baseline data from edoxaban treatment in routine clinical practice for patients with atrial fibrillation (AF) in Europe (ETNA-AF-Europe)
    De Caterina, Raffaele
    Kelly, Peter
    Monteiro, Pedro
    Deharo, Jean Claude
    de Asmundis, Carlo
    Lopez-de-Sa, Esteban
    Weiss, Thomas W.
    Waltenberger, Johannes
    Steffel, Jan
    de Groot, Joris R.
    Levy, Pierre
    Bakhai, Ameet
    Zierhut, Wolfgang
    Laeis, Petra
    Kerschnitzki, Michael
    Reimitz, Paul-Egbert
    Kirchhof, Paulus
    BMC CARDIOVASCULAR DISORDERS, 2019, 19 (1)
12345